Wyeth Upgrades St. Louis Facilities

Published October 2002

ST. LOUIS -

Wyeth has worked with McCarthy to upgrade its St. Louis facilities, purchased in 1998, for the production of the hemoophilia drug ReFacto®. McCarthy has completed more than 500 projects for a total of almost $30 million to ready the cGMP manufacturing facilities, labs, warehouse and offices for Wyeth's manufacturing needs. Currently, the St. Louis facility is the only one in the United States producing ReFacto®. Flad & Associates of Madison, Wisc., has provided architectural services.

Copyright 2008 Tradeline Inc.
All Rights Reserved
ISSN: 1096-4894